Searched for
TAXIM
Pharma stocks: Time to change the prescription? 13 pharma stocks with an upside potential of up to 39%Close to three decades back, when Indian pharma firms began to move into the US market, they faced many challenges. And the fact is that th...- Healthcare stocks: Better to own a collection? 16 stocks from different segments with upside potential of 10 to 35% in 1 yearBefore you read on, be clear about one thing. The stocks on our list today are expensive in terms of valuations and may well witness correc...
- Stock picks of the week: 5 stocks with consistent score improvement and return potential of more than 32% in 1 yearIn the long run, it is the bulls who always win. There is ample evidence to back this assertion. But, for the bulls to be successful in the...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%Last Friday might be an exception but for the last few weeks, everything on the street appears good and green. When it happens, there is a ...
- These healthcare and pharma stocks may deliver more than 20% in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 31 %There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Wi...
- Fundamental tailwinds are a stronger play than volatile markets? 5 Indian pharma stocks with upside potential of up to 41%There is no doubt that the market is going through a volatile phase and bears are once again telling the street to never write them off. Wi...
- Tailwinds at the right time: 7 pharma stocks with an upside potential up to 37 %It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case o...
- After a long winter finally some tailwinds; 6 pharma stocks with upside potential of up to 31%While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...
- Nifty healthcare index stocks; Staying bullish on select pharma and hospitalsWhile they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...
- Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MDAlkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and co...
- Alkem Labs to grow chronic therapies to drive future growth: MDThe Mumbai-based drug maker, which entered the US generics market over a decade ago, is also scaling back its investments in oral solids in...
- Government prohibits 328 fixed dose combinationsThe ban is effective immediately and may shave off over Rs 1,500 crore from India’s Rs 1.18 lakh crore pharmaceutical industry
- Health ministry to ban 328 combination medicines over safety concernsET has viewed parts of the latest ban notifications, which a senior ministry official confirmed would be notified this week.
- Paytm founder Vijay Shekhar Sharma youngest Indian billionaireOf the 2,208 billionaires in Forbes' 2018 list of the world's richest, just 63 are under the age of 40 and more than half (34) are self-mad...
- NPPA cuts antibiotic, stomach ulcer and abortion drug prices by 30%Indian drug pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has cut prices of 24 more essential medicines.
- Pharmaceutical company Alkem Laboratories eyeing big-bang IPO in FY-1580% of the company's revenues currently come from domestic operations and now it's main focus is on the US market.
- Pharma growth slows down to 9.6%Growth in the domestic pharma market dipped in September over the previous month, but was still nearly double digit at 9.6%.
- Pharma cos’ sales jump 10% in MayPharma companies have recorded robust sales in May 2009, as per ORG IMS data, with a moving annual total (MAT) of 10.4% at Rs 36,048 crore ...
- Shrinking pie forces pharma to build brandsIndian pharma companies which paid little focus on building brands will soon have to do so.
Load More
